Novartis AG (NVS)'s Lucentis Fails to Win Backing for Eye Condition in U.K. Review  
11/30/2011 7:17:51 AM

Novartis AG (NOVN)’s Lucentis eye drug failed to win the backing of the U.K.’s health-cost agency in final guidelines on the treatment of diabetic macular edema. Novartis underestimated the cost of the medicine because some patients need therapy in both eyes, the National Institute for Health and Clinical Excellence said today in an e-mailed statement. The agency, known as NICE, advises the state-run National Health Service on which treatments represent value for money. Today’s decision mirrors a preliminary one in July.